An Overview of Olaparib as a treatment option for metastatic castration-resistant prostate cancer

Expert Opin Pharmacother. 2021 Jul 12. doi: 10.1080/14656566.2021.1952983. Online ahead of print.ABSTRACTINTRODUCTION: : Men with prostate cancer undergoing castration will eventually progress. In addition to androgen receptor pathway inhibitors (like abiraterone and enzalutamide) or chemotherapy (like docetaxel), exists olaparib, a relatively new drug that interferes with the base excision repair (BER) pathway mainly due to selective inhibition of Poly ADP-ribose polymerase (PARP) 1 and 2.AREAS COVERED: : Herein, the authors evaluate the basic characteristics of olaparib, including its pharmacokinetics, mechanism of action, efficacy and safety profile. The authors also provide their expert opinion and future perspectives for the place of this drug in the current treatment armamentarium.EXPERT OPINION: : Olaparib is the first drug to prove that genetic sequencing and precise medicine is a viable and important option for prostate cancer patients. In patients with deletions in pre-selected genes, its efficacy renders it as a viable option for second- or third-line management of metastatic castrate resistance prostate cancer (mCRPC). This fact, along with its acceptable toxicity profile, provide physicians with a new weapon in their armamentarium against this extremely difficult to treat disease.PMID:34252319 | DOI:10.1080/14656566.2021.1952983
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research